Last updated on May 2020

Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Brief description of study

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).

Clinical Study Identifier: NCT03539536

Find a site near you

Start Over

Highlands Oncology Group /ID# 215600

Fayetteville, AR United States
  Connect »